Project Grant R44AI125168

The Defense Health Agency awarded Flugen Inc. a $6,237,445 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to optimize downstream recovery and stabilization of the drug substance for their intranasal influenza vaccine. The three-year grant also supports research on concurrent administration of Flugen's H3N2 M2SR monovalent influenza vaccine with inactivated flu vaccines in older adult populations. This award builds on Flugen's previous federal grants...

Viva Viral Vaccines, Inc. received a $299,968 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 25, 2025, through August 31, 2026. The project is being conducted in Ithaca, New York. The award funds development of a broad-spectrum, multivalent vaccine platform targeting influenza neuraminidase (NA) protein that addresses critical limitations in current...

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $256,000 will develop Recombinant BCG as a novel immunoadjuvant for viral infections. The awardee, Oncosting LLC located in Baltimore, Maryland, will optimize media and lyophilization manufacturing of BCG-STING, evaluate its immunological effects as an adjuvant for H1N1 influenza vaccination, and assess its protective effects as an H1N1 vaccine adjuvant. By adding stimulator of...

Invvax, Inc. received a $996,606 Cooperative Agreement from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) effective July 1, 2025, through June 30, 2027. The award supports a Small Business Innovation Research (SBIR) Phase II project focused on developing Stable Prophylactic Antibodies (SPABs) that maintain efficacy over extended periods. The primary deliverable is the creation of enhanced antibody mutations that significantly...

Federal Grant Award Summary Via Therapeutics, LLC received a $314,363 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 11, 2025, through August 31, 2026. The company is developing a microneedle-based messenger RNA (mRNA) flu vaccine candidate designed for transcutaneous (intradermal) immunization. The project leverages Via Therapeutics' proprietary thin-film...

Flugen Inc. was awarded a $5.6 million Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) for the period of April 1, 2023 through March 31, 2026. The grant will support Flugen's work to develop scalable manufacturing and toxicity testing methods for an intranasal M2SR influenza vaccine. The Military Medical Research and Development program aims to transform military and public health through innovative medical...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $661,313 Project Grant (R01) to Massachusetts General Hospital's Ragon Institute, effective February 6, 2026 through January 31, 2031, under the Allergy and Infectious Diseases Research program (CFDA 93.855). Principal Investigator Dr. Daniel Lingwood and Co-Investigator Dr. Batista are developing a universal influenza A vaccine by eliciting broadly neutralizing antibodies (BNAbs) through...

Federal Project Grant Award Summary Massachusetts General Hospital received a $676,666 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 3, 2025, with a completion date of August 31, 2030. The award funds research into spatial and temporal adjuvant delivery mechanisms designed to enhance messenger RNA (mRNA) vaccine efficacy and durability. The project will...

This Project Grant award from the National Institute of Allergy and Infectious Diseases supports the development of a novel plant-based source for squalene as a natural vaccine adjuvant. The $514,006 award to Synshark LLC supports research to engineer tobacco plants to stably produce and accumulate squalene on their leaves. This work directly relates to the commercialization plan to provide a non-animal, indoor grown natural adjuvant for vaccines. Currently, squalene used in vaccines is...

This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...